Kintara Therapeutics Inc

NASDAQ:KTRA   3:59:50 PM EDT
1.58
-0.05 (-3.07%)
Products, Regulatory

Kintara Reports Topline Results From Phase 2 Clinical Trial Of VAL-083 For Recurrent GBM

Published: 07/01/2021 12:12 GMT
Kintara Therapeutics Inc (KTRA) - Kintara Reports Topline Results From Phase 2 Clinical Trial of Val-083 for Recurrent Gbm.
Kintara Therapeutics Inc - Median Overall Survival for 48 Efficacy Evaluable Patients Initially Receiving Treatment Dose of 30 Mg/m2/day is 8.0 Months.
Kintara Therapeutics Inc - in 30 Mg/m2/day Starting Dose Cohort, Five Patients Experienced a Serious Adverse Event (sae) Possibly Related to Val-083.